Accipiter Biosciences

Accipiter Biosciences designs de novo multi-specific protein therapeutics using AI from David Baker's Institute for Protein Design. The company creates entirely new proteins that bind multiple cellular targets simultaneously, enabling novel mechanisms of action against complex diseases. Accipiter emerged from stealth in November 2025 with a $330M+ Pfizer deal and a Kite Pharma partnership already in place.

$12.7M

Total raised

Proprietary computational methods from UW Institute for Protein Design to create de novo proteins that bind multiple cellular targets simultaneously. Platform enables in silico design-to-lab validation in under 2 months.